Abstract
Background: Randomized control trials and observational studies show high-quality warfarin therapy leads to safe and effective stroke prophylaxis. In usual community practice, patient, physician and health care system factors are barriers to optimal anticoagulation. We examined the predictive relationship between inpatient and outpatient INR values in chronic non-valvular atrial fibrillation (AF) patients hospitalized for ischemic stroke (S), bleed (B) and control events (C) in usual community practice.
Methods: This nested case-control analysis identified AF patients hospitalized for S, B and C using medical and pharmacy claims spanning 4.5 years (‘98–‘03) and validating diagnosis with chart abstraction. AF was defined as 2 medical claims for AF ≥ 42 days apart with a related prescription claim for warfarin. INRs from both outpatient and inpatient settings were used to yield a continuous history of coagulation status. Time-in-therapeutic-range (TTR) was calculated by Rosendaal’s linear interpolation method. Correlation of inpatient and prognostic utility of last outpatient INRs was tested with S or B hospitalizations using univariate and multivariate logistic regression.
Results: Overall, 614 hospitalizations (means: age 73.9, CHADS2 = 3.24; 52% male) included S (n = 98), B (n = 101) and C (n = 415) events. Average TTR was 28.6% (49.4% at INR <2.0, 21.9% at INR >3.0). First INR on admission (INR <2.0 or >3.0) was associated with S and B hospitalizations (OR-adjusted [95%CI], 1.68 [1.04–2.73] and 1.72 [1.02–2.90]), respectively. Last outpatient INR <2.0 was not associated with S (OR-adjusted [95%CI], 1.12 [0.77–1.81]), and INR >3.0 was not associated with B (OR-adjusted [95%CI], 1.25 [0.67–2.32]). Last outpatient INR measurement occurred at 28, 22 and 24 days (median; S, B & C, respectively) before hospitalization.
Conclusion: Patients were observed within therapeutic range less than 30% of their time on warfarin. While inpatient INRs were clearly associated with both ischemic stroke and bleed events, last outpatient INR before event was not predictive.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Heart Association (2004) Heart Disease and Stroke Statistics—2004 Update. AHA 2–50
Singer DE, Albers GW, Dalen JE, et al. (2004) Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:429S–456S
Diringer MN, Edwards DF, Mattson DT, et al. (1999) Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke 30:724–728
(1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 323:1505–1511
(1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342:1255–1262
(1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348:633–638
Ezekowitz MD, Bridgers SL, James KE, et al. (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:1406–1412
Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S (2004) Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:287S–310S
Matchar DB (2003) Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. Card Electrophysiol Rev 7:379–381
Aronow WS, Ahn C, Kronzon I, Gutstein H (1999) Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc 47:366–368
Caro JJ, Flegel KM, Orejuela ME, et al. (1999) Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ 161:493–497
Evans A, Perez I, Yu G, Kalra L (2001) Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 32:2828–2832
Evans A, Kalra L (2001) Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 161:1443–1447
Gage BF, Boechler M, Doggette AL, et al. (2000) Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 31:822–827
Go AS (2004) Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care 10:S58–S65
Kalra L, Yu G, Perez I, Lakhani A, Donaldson N (2000) Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 320:1236–1239
Samsa GP, Matchar DB, Goldstein LB, et al. (2000) Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 160:967–973
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239
Gage BF, Waterman AD, Shannon W, et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870
Bushnell CD, Matchar DB (2004) Pharmacoeconomics of atrial fibrillation and stroke prevention. Am J Manag Care 10:S66–S71
Ansell J, Hirsh J, Poller L, et al. (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:204S–233S
Casey M, Hanley K (2001) A measurement of the efficacy of anticoagulation monitoring in a general practice based setting. Ir Med J 94:245–246
Willey VJ, Bullano MF, Hauch O, et al. (2004) Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 26:1149–1159
(1991) Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation 84:527–539
Hylek EM, Go AS, Chang Y, et al. (2003) Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. NEngl J Med 349:1019–1026
(1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457
Go AS, Hylek EM, Chang Y, et al. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290:2685–2692
Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE (2002) Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 113:42–51
Armstrong EP, Manuchehri F (1997) Ambulatory care databases for managed care organizations. Am J Health Syst Pharm 54:1973–1983
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sarawate, C., Sikirica, M.V., Willey, V.J. et al. Monitoring anticoagulation in atrial fibrillation. J Thromb Thrombolysis 21, 191–198 (2006). https://doi.org/10.1007/s11239-006-4968-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-006-4968-z